Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Evrard

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|July 10, 2024
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation studyAntoine Adenis, François Ghiringhelli, Ludovic Gauthier, et al.
Molecular Cancer Therapeutics|December 17, 2002
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via FasJoseph Ciccolini, Frédéric Fina, Karine Bezulier, et al.
BMC Medical Genetics|October 28, 2011
A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsiaKevin Mouzat, Eric Mercier, Anne Polge, et al.
Clinical Pharmacokinetics|April 27, 2016
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer PatientsLitaty Céphanoée Mbatchi, Jacques Robert, Marc Ychou, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2017
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancerLitaty C Mbatchi, Matthieu Gassiot, Philippe Pourquier, et al.
Therapeutic Drug Monitoring|December 17, 2009
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabineCaroline Raynal, Joseph Ciccolini, Cédric Mercier, et al.
Bulletin Du Cancer|August 15, 2018
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]Florian Lemaitre, Françoise Goirand, Manon Launay, et al.
The New Phytologist|January 15, 2016
Avr4 promotes Cf-4 receptor-like protein association with the BAK1/SERK3 receptor-like kinase to initiate receptor endocytosis and plant immunityJelle Postma, Thomas W H Liebrand, Guozhi Bi, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiencyJoseph Ciccolini, Cedric Mercier, Laetitia Dahan, et al.
The Journal of Antimicrobial Chemotherapy|October 3, 2015
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsisClaire Roger, Bastian Nucci, Benjamin Louart, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|July 10, 2024
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation studyAntoine Adenis, François Ghiringhelli, Ludovic Gauthier, et al.
Molecular Cancer Therapeutics|December 17, 2002
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via FasJoseph Ciccolini, Frédéric Fina, Karine Bezulier, et al.
BMC Medical Genetics|October 28, 2011
A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsiaKevin Mouzat, Eric Mercier, Anne Polge, et al.
Clinical Pharmacokinetics|April 27, 2016
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer PatientsLitaty Céphanoée Mbatchi, Jacques Robert, Marc Ychou, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2017
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancerLitaty C Mbatchi, Matthieu Gassiot, Philippe Pourquier, et al.
Therapeutic Drug Monitoring|December 17, 2009
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabineCaroline Raynal, Joseph Ciccolini, Cédric Mercier, et al.
Bulletin Du Cancer|August 15, 2018
[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer]Florian Lemaitre, Françoise Goirand, Manon Launay, et al.
The New Phytologist|January 15, 2016
Avr4 promotes Cf-4 receptor-like protein association with the BAK1/SERK3 receptor-like kinase to initiate receptor endocytosis and plant immunityJelle Postma, Thomas W H Liebrand, Guozhi Bi, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2005
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiencyJoseph Ciccolini, Cedric Mercier, Laetitia Dahan, et al.
The Journal of Antimicrobial Chemotherapy|October 3, 2015
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsisClaire Roger, Bastian Nucci, Benjamin Louart, et al.
Pageof 7